You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – The European Commission has approved gilteritinib (Astellas' Xospata) as a treatment for adult acute myeloid leukemia who have relapsed or refractory disease characterized by FLT3 mutations.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.